Progress on N56 road projects welcomed

first_imgDeputy Pat the Cope Gallagher Leas Cheann Comhairle has welcomed confirmation from Transport Infrastructure Ireland (TII) that steady progress is being made on the three N56 road projects. A contractor has been appointed for the N56 Dungloe to Glenties to construct the road section between Kilkenny to Letterlily. A request to appoint a contractor is expected in the next few weeks for the N56 project for Coolboy to Kilmacrennan. Regarding the third project – the N56 Mountcharles to Drumbeigh – ongoing assessment of the tenders is underway and a contractor is expected to be appointed by the end of December. Pat the Cope said: “I welcome the progress being made on these road projects at present and I will maintain the pressure on the TII and the Government in order to get actual road construction started.”Transport Infrastructure Ireland (TII) has confirmed the following updates on the progress of current N56 projects within the county at present.  The Kilkenny to Letterlily N56 contract has been awarded by Donegal County Council to Fox contracting. The planned improvement scheme covering from Kilkenny to Letterilly on the Glenties to Dungloe road will involve widening and realignment to Type 3 Single Carriageway (6.0m Carriageway with 0.5m hard strips). The project also includes a cycle track for its full length. The scheme is 3.6km long and has an estimated completion cost of €12 million euro. The Coolboy to Kilmacrennan N56 tender assessment is ongoing we expect to receive a request from Donegal County Council to award this contract in December 2017. The proposed N56 Coolboy Kilmacrennan scheme is located an approximate   5 km north of Letterkenny and is a continuation of the N56 Mountaintop to Illistrin project completed in 2009. The existing road is narrow (approximately 6m wide with neither shoulders nor verges) and has a substandard horizontal and vertical alignment. There are 5 local road junctions with restricted junction visibility on this section. The 3.15km long scheme will involve the widening and realignment to Type 2 Single Carriageway (7.0m Carriageway with hard strips) of the N56. The project will significantly improve safety for road users and will maintain consistency of cross-section between Letterkenny and Kilmacrennan.Tenders were received on the Mountcharles to Drumbeigh N56 scheme last week and will be subject to assessment over the coming weeks.  The proposed works will involve the design and construction of approximately 2.75km of new National Secondary Road to Type 1 Single Carriageway. This scheme commences at the tie-in with the Mountcharles Bypass and continues to Drumbeigh and when complete the project will cost an approximate €15 million.Pat the Cope added: “It is critical that we continue to invest in our roads within the county, especially in the context of the forthcoming Brexit and the very increasing rural – urban imbalance which exists in this country. “Infrastructural investment in rural areas is essential to act as a catalyst for future growth and regional development. “I expect that Donegal County Council and the TII will now put in place further plans for future investment in the N56 along with investment in the N13, N14 and the  N15 ; all of these National roads provide critical access to our county and our regions and as such warrant sizeable investment by central Government,” concluded Pat the Cope. Progress on N56 road projects welcomed was last modified: November 27th, 2017 by Rachel McLaughlinShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window) Tags:N56last_img read more

Scientists find how immune system helps to clear HBV infection after treatment

first_imgMay 17 2018Scientists from Karolinska Institutet and Hannover Medical School have published two studies that provide insights into how the immune system responds and helps to clear a hepatitis B infection after treatment interruption. The findings offer a framework for future tailored treatment strategies and are published in The Journal of Infectious Diseases and Journal of Hepatology.Chronic hepatitis B (CHB) caused by hepatitis B virus (HBV), affects 250 million individuals worldwide. The virus infects the liver and infected patients are at risk of developing liver cirrhosis and liver cancer.Nucleoside/nucleotide analogues (NAs) are the most commonly used drugs to treat CHB, but this treatment only suppresses the virus and rarely leads to eradication of the infection. Thus, for most patients this is a life-long treatment.The immune system recovers in some patientsRelated StoriesLiving with advanced breast cancerNanotechnology-based compound used to deliver hepatitis B vaccineStudy reveals link between inflammatory diet and colorectal cancer riskBecause of this, new treatment strategies are continuously evaluated with the aim to achieve elimination of HBV. One involves doing a structured NA treatment interruption in patients that have been on the treatment for a couple of years. In 20-30 per cent of the CHB patients the immune system recovers from being exhausted by the chronic infection and gains the capacity to efficiently fight the virus when it starts to replicate after the treatment has been discontinued.In a clinical trial 15 patients with CHB underwent a structured treatment cessation. Before, during and after, the patients were closely monitored and biological samples were continuously collected for subsequent analysis using flow cytometry. The research focus was on the parts of the immune system that has the capacity to recognize and eliminate virus-infected liver cells.”Interruption of NA treatment significantly boosts the capacity of immune cells to kill HBV-infected cells and this activation was also associated with functional cure in the patients. For patients clearing the infection, we also found that the immune system was less exhausted and that immune cells specific for the virus expanded in vivo,” says PhD-student Christine Zimmer at the Department of Medicine, Huddinge, Karolinska Institutet.Further studies necessaryEven though patient recruitment for this kind of clinical trial is extremely challenging, the findings need to be confirmed in larger studies.”Several questions still remain to be answered such as the identification of the exact component of the immune system needed to achieve a functional cure of CHB following NA interruption, and also identifying patients who will benefit from stopping NA treatment,” says Niklas Björkström, Physician and Associate Professor at the Department of Medicine Huddinge, Karolinska Institutet, one of the main authors. Source: read more